Short answer
Spyre Therapeutics, Inc. (SYRE) filed an 8-K current report with the SEC on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
Spyre Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Investor-relevant figures and management commentary contained in Exhibit 99.1
- Results provide the latest view of Spyre’s cash position, operating expenses and clinical-development funding needs
Item EX-99.1 · Exhibit EX-99.1
- SPY003 completed positive IBD monotherapy proof-of-concept, supporting progression toward potentially differentiated combination therapies
- SKYLINE Part B enrolling ahead of schedule, with increased enrollment and three combination induction readouts expected Q3 2027
- SPY072 showed RA activity but missed internal advancement standards, while PsA and axSpA failures ended rheumatic-disease development
- HS strategy strengthened through SKYLIGHT initiation and planned pivotal SPY072 program, targeting a market forecast above $10 billion by 2035
- Pro forma liquidity $1,467.9 million, including $378.0 million offering proceeds and $18.0 million ATM sales, supporting runway into second half 2029
- Q3 net loss widened to $96.1 million from $11.2 million, with R&D expense rising to $89.2 million from $45.2 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Spyre Therapeutics, Inc. 8-K filings
Get the next SYRE 8-K as it lands
Follow SYRE for push alerts, or ask the research agent what this filing means.